Genprex (NASDAQ:GNPX) Posts Quarterly Earnings Results

Genprex (NASDAQ:GNPX) posted its quarterly earnings results on Wednesday. The company reported ($0.64) earnings per share for the quarter, Zacks reports.

Genprex Trading Up 2.5%

Shares of NASDAQ:GNPX traded up $0.02 during midday trading on Wednesday, hitting $0.85. 178,655 shares of the stock were exchanged, compared to its average volume of 1,019,538. The stock has a market cap of $8.87 million, a P/E ratio of -0.03 and a beta of -0.94. Genprex has a twelve month low of $0.81 and a twelve month high of $55.00. The company has a 50 day moving average price of $1.47 and a 200-day moving average price of $2.47.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Genprex presently has a consensus rating of “Sell”.

Institutional Trading of Genprex

An institutional investor recently raised its position in Genprex stock. Susquehanna International Group LLP lifted its holdings in shares of Genprex (NASDAQ:GNPX) by 11.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 340,056 shares of the company’s stock after purchasing an additional 35,661 shares during the period. Susquehanna International Group LLP owned about 27.20% of Genprex worth $58,000 as of its most recent SEC filing. Institutional investors and hedge funds own 14.05% of the company’s stock.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.